Acadia Revives Nuplazid’s Chances In Schizophrenia With Negative Symptom Data
Executive Summary
After a Phase III failure in refractory schizophrenia, Acadia has Phase II data showing efficacy in negative symptoms of the disease, an unmet need. It plans a pivotal study in 2020.
You may also be interested in...
Acadia’s Nuplazid Shows Nearly Three-Fold Reduction In Psychosis Relapse
Data presented at the CTAD meeting for pimavanserin in dementia-related psychosis will support an sNDA filing in 2020 for an approval that could broaden the drug’s market exponentially.
Pimavanserin Fails In ENHANCE But Other CNS Uses Targeted
Acadia halts evaluation of pimavanserin as a schizophrenia adjunct but continues study of effect on negative symptoms and in other CNS conditions.
Allergan Seeks Quick Vraylar Turnaround After US FDA Refuses To File
Supplemental application for negative symptoms associated with schizophrenia has robust data, Datamonitor Healthcare analyst suggests, but was incomplete.